| Study | Outcome (unit) | Followup (years) | N Analyzed | Group | Results | Between Group Differences |
| --- | --- | --- | --- | --- | --- | --- |
| Belch, 2008 (POPADAD)57  Fair | Cancer death (number of participants) | 6.7 | 318 | ASA alone | 9 (2.8%) | ASA vs. No ASA: OR 0.80 (95% CI, 0.47 to 1.37) |
| 320 | ASA + antioxidant | 16 (5%) |
| 320 | Antioxidant alone | 18 (5.6%) |
| 318 | Placebo alone | 13 (4.1%) |
| Brighton, 2012 (ASPIRE)58  Good | Cancer death (number of participants) | 3.1 | 411 | ASA | 6 (1.5%) | NR |
| 411 | Placebo | 4 (1.0%) |
| CDPRG, 1980 (CDPA)59  Good | Cancer death (number of participants) | 1.8 | 758 | ASA | 1 (0.1%) | ASA vs. Placebo: Z-value -0.98, p=NR |
| 771 | Placebo | 3 (0.4%) |
| Cook, 2005 (WHS)60  Good (KQ1,KQ2); Fair (KQ6) | Cancer death (number of participants) | 10.1 | 19934 | ASA | 284 (1.4%) | ASA vs. No ASA: RR 0.95 (95% CI, 0.81 to 1.11), p=0.51\* |
| 19942 | No ASA | 299 (1.5%) |
| Cancer death, lung (number of participants) | 10.1 | 19934 | ASA | 58 (0.3%) | ASA vs. No ASA: HR 0.70 (95% CI, 0.50 to 0.99), p=0.04\* |
| 19942 | No ASA | 82 (0.4%) |
| *Cook, 2013 (Companion publication to Cook, 2005)88*  *Good* | *Cancer death (number of participants)* | *18* | *19934* | *ASA* | *729 (3.7%)* | *ASA vs. No ASA: HR 0.97 (95% CI, 0.88 to 1.07), p=0.56\** |
| *19942* | *No ASA* | *748 (3.8%)* |
| DAMAD, 198951  Fair | Cancer death, jaw (number of participants) | 3 | 157 | ASA | 1 (0.6%) | NR |
| 157 | Placebo | 0 (0%) |
| de Gaetano, 2001 (PPP)61  Fair | Cancer death (data from Rothwell 201210) (number of participants) | 3.6 | 2226 | ASA | 31 (1.4%) | ASA vs. No ASA: OR 1.09 (95% CI, 0.66 to 1.82) |
| 2269 | No ASA | 29 (1.3%) |
| Diener, 1997 (ESPS-2)62  Good | Cancer death (number of participants) | 2 | 1649 | ASA | 20 (1.2%) | NR |
| 1649 | Placebo | 24 (1.5%) |
| Cancer death (data from Rothwell 201210) (number of participants) | 2 | 1649 | ASA | 19 (1.2%) | ASA vs. Placebo: OR 0.79 (95% CI, 0.43 to 1.45) |
| 1649 | Placebo | 24 (1.5%) |
| EAFT, 199363  Fair | Cancer death (data from Rothwell 201210) (number of participants) | 2.3 | 404 | ASA | 10 (2.5%) | ASA vs. Placebo: OR 0.77 (95% CI, 0.33 to 1.81) |
| 378 | Placebo | 12 (3.2%) |
| ETDRS, 199264  Good | Cancer death (number of participants) | 5 | 1856 | ASA | 16 (0.9%) | ASA vs. Placebo: Z-value 0.37, p=NR; OR 1.14 (95% CI, 0.56 to 2.35) |
| 1855 | Placebo | 14 (0.8%) |
| Farrell, 1991 (UK-TIA)65  Fair | Cancer death (data from Rothwell 201210) (number of participants) | 4 | 1621 | ASA | 24 (1.5%) | ASA vs. Placebo: OR 0.47 (95% CI, 0.27 to 0.84) |
| 814 | Placebo | 25 (3.1%) |
| Cancer death (number of participants) | 4 | 815 | ASA 1200 | 12 (1.5%) | NR |
| 806 | ASA 300 | 9 (1.1%) |
| 814 | Placebo | 23 (2.8%) |
| Fowkes, 2010 (AAA)66  Good | Cancer death (data from Rothwell 20118) (number of participants) | 8.2 | 1675 | ASA | 78 (4.7%) | ASA vs. No ASA: OR 0.86 (95% CI, 0.63 to 1.17) |
| 1675 | No ASA | 90 (5.4%) |
| Hansson, 1998 (HOT)67  Fair | Cancer death (data from Rothwell 201210) (number of participants) | 3.8 | 9399 | ASA | 108 (1.1%) | ASA vs. Placebo: OR 1.03 (95% CI, 0.78 to 1.35) |
| 9391 | Placebo | 105 (1.1%) |
| Logan, 2008 (ukCAP)68  Fair | Carcinoma-related deaths (number of participants) | 3.4 | 236 | ASA alone | 2 (0.8%) | NR |
| 236 | ASA + folic acid | 0 (0%) |
| 234 | Folic acid alone | 1 (0.4%) |
| 233 | Placebo alone | 2 (0.9%) |
| Intracerebral malignant tumor, death (number of participants) | 3.4 | 236 | ASA alone | 0 (0%) | NR |
| 236 | ASA + folic acid | 0 (0%) |
| 234 | Folic acid alone | 0 (0%) |
| 233 | Placebo alone | 1 (0.4%) |
| Lung cancer, death (number of participants) | 3.4 | 236 | ASA alone | 1 (0.4%) | NR |
| 236 | ASA + folic acid | 0 (0%) |
| 234 | Folic acid alone | 1 (0.4%) |
| 233 | Placebo alone | 1 (0.4%) |
| Pancreatic cancer, death (number of participants) | 3.4 | 236 | ASA + folic acid | 0 (0%) | NR |
| 236 | ASA alone | 1 (0.4%) |
| 234 | Folic acid alone | 0 (0%) |
| 233 | Placebo alone | 0 (0%) |
| MRC, 1998 (TPT)69  Good | Cancer death (number of participants) | 6.8 | 1268 | ASA | 49 (3.9%) | NR |
| 1272 | Placebo | 51 (4.0%) |
| Ogawa, 2008 (JPAD)70  Fair | Cancer death (number of participants) | 4.37 | 1262 | ASA | 15 (1.2%) | ASA vs. No ASA: OR 0.80 (95% CI, 0.40 to 1.57) |
| 1277 | No ASA | 19 (1.5%) |
| PARIS, 198071  Good | Cancer death (number of participants) | 3.4 | 810 | ASA | 7 (0.9%) | ASA vs. Placebo: Difference 0.62; Z-value 1.10, p=NR† |
| 406 | Placebo | 1 (0.2%) |
| Peto, 1988 (BMD)72  Fair | Cancer death, lung (per 10,000 person-years) | 6 | 3429 | ASA | 7.4 (NR) | NR |
| 1710 | No ASA | 11.6 (NR) |
| Cancer death, other (per 10,000 person-years) | 6 | 3429 | ASA | 26.6 (NR) | NR |
| 1710 | No ASA | 31.7 (NR) |
| Cancer death, upper digestive tract (per 10,000 person-years) | 6 | 3429 | ASA | 5.8 (NR) | NR |
| 1710 | No ASA | 5.3 (NR) |
| Cancer death (data from Rothwell, 201210) (number of participants) | 6 | 3429 | ASA | 75 (2.2%) | ASA vs. No ASA: OR 0.79 (95% CI, 0.55 to 1.14) |
| 1710 | No ASA | 47 (2.7%) |
| PHS, 198973  Good (KQ1); Fair (KQ6) | Cancer death (data from Seshasai 201244) (number of participants) | 5 | 11037 | ASA | 79 (0.7%) | ASA vs. No ASA: OR 1.16 (95% CI, 0.84 to 1.61), p=NR |
| 11034 | No ASA | 68 (0.6%) |
| SALT, 199174  Good | Cancer deaths (data from Rothwell 201210) (number of participants) | 2.67 | 676 | ASA | 12 (1.8%) | ASA vs. Placebo: OR 0.75 (95% CI, 0.65 to 1.61) |
| 684 | Placebo | 16 (2.3%) |
| Death due to malignant disorders (number of participants) | 2.67 | 676 | ASA | 10 (1.5%) | NR |
| 684 | Placebo | 15 (2.2%) |

\*Adjusted by age, vitamin E and beta-carotene treatment assignment

†Adjustment for baseline differences across treatment groups

**Abbreviations**: ASA = acetylsalicylic acid; CI = confidence interval; HR = hazard ratio; NR = not reported; OR = odds ratio; RR = relative risk; vs = versus